Friday, 15 Dec 2017

You are here

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

  1. In RA, Smoking status recorded in 40%; cessation counseling in only 10% & was less likely when RA was controlled. https://buff.ly/2wWaHs2 
  2. ~1/3 RA pts rank their Disease activity higher than their Rheumatologist; more likely seronegative RA, those in LDAS with FM, Depression, high pain scores. https://buff.ly/2xygaK0 
  3. Higher MASEI (enthesitis) scores in PsA associated with more Joint damage, ankylosis, arthritis mutilans periostitis, axial Disease. https://buff.ly/2fU0k25 
  4. Review shows antiphopholipid Abs associated with and increased risk of idiopathic pulm arterial HTN, left-side valvular heart dz https://t.co/79KG9Qfb6k
  5. CDC: STDs new record high #s in 2016 - chlamydia (1.6mil), gonorrhea (470k) & syphilis (28k); more screening urged https://t.co/U6bsHAeWQa
  6. In Australia from 2015 to 2030, OA numbers are expected to increase 41%; RA by 37%, with cost of care rising by 37% for both. https://t.co/BNc2P4CyU3
  7. Mayo: 1996 to 2013, 58 cases of AAV in Olmstead Co - 23 GPA, 28 MPA & 7 EGPA. 60% MPO+, 30% PR3+: Prev 42.1/100,000 https://t.co/Q0n2Srmf7t
  8. Olmstead Co. Mayo Clinic study shows asthma significantly associated with increased risk of RA (adj OR 1.74) https://t.co/lcqkjGu9BK 
  9. Kevzara (sarilumab) has been recommended by UK NICE for use with MTX in adults with severe, active RA https://t.co/2fL8LDjLi3
  10. FDA Panel Backs New Zoster Subunit Vaccine
  11. Sirukumab Turned Down by FDA
  12.  Psoriasis Increases Risk of Major Adverse Cardiovascular Events  
  13. Increased Deaths in RA, Despite Decreasing Mortality Rates
  14. No Cancer Risk With Biologic Use
  15. The DownEaster Meeting – Westborough, MA  14 October 2017  
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 15 December 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com. 

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations.